Silk Road Medical to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
Silk Road Medical (NASDAQ: SILK) announced it will report its fourth quarter and full year 2021 financial results after market close on February 24, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silk Road Medical (NASDAQ: SILK) announced it will report its fourth quarter and full year 2021 financial results after market close on February 24, 2022. A conference call will follow at 1:30 PM PT / 4:30 PM ET. Investors can join the call by dialing (844) 883-3861 or (574) 990-9820 for international callers, using conference ID: 2046067. This session will provide insights into the company's strategies and financial performance in stroke risk reduction through its innovative TransCarotid Artery Revascularization (TCAR) procedure.
Details
News Market Reaction – SILK
The recorded move for SILK in the trading session of this news was +2.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 2046067. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.